MAR 10, 2015 09:00 AM PDT

Newly Updated Guidelines for the Diagnosis of Multiple Myeloma

SPONSORED BY: Binding Site, Binding Site
C.E. CREDITS: CE
Speakers
  • Professor of Medicine & Chief of Multiple Service at Memorial Sloan-Kettering in New York City
    Biography
      Dr. Landgren is Professor of Medicine and Chief Attending Physician of the Myeloma Service at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, NY. Dr. Landgren is one of the world leaders in the field of early treatment strategies and molecular- and cell-based monitoring of minimal residual disease (MRD) detection in multiple myeloma and its precursor states. He leads a translational research program at MSKCC designed to discover new treatment paradigms integrating modern therapy and novel MRD assays. Dr. Landgren has designed and led the definitive study showing that all multiple myeloma patients are preceded by a precursor stage. As part of his ongoing research program, he is studying molecular mechanisms underlying the trajectory from precursor to full-blown multiple myeloma with the goal to develop of treatment strategies aiming to delay, prevent, and ultimately define a cure for multiple myeloma.

      Dr. Landgren has published over 250 peer-reviewed publications and he is a frequently invited speaker at national and international hematology conferences. He serves on several research committees and editorial boards for scientific journals.

    Abstract:
    DATE: Tuesday, March 10, 2015
    TIME: 09:00 PST, 11:00 CST, 12:00 EST, 16:00 GMT


    The International Myeloma Working Group (IMWG) has issued updated criteria for the diagnosis of multiple myeloma.

    The updated criteria, published in The Lancet Oncology represent a significant change in how Multiple Myeloma is diagnosed and the stage at which patients should be treated.

    Join us on March 10th on a webinar covering these updated criteria for Myeloma and related plasma cell disorders and the importance of biomarkers in Early Stage Disease.
    ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
    Following this presentation the listener will:
    • Understand the history and traditional tools used to diagnose Myeloma
    • Gain an appreciation for the evolution of Myeloma diagnosis and biomarkers of the disease
    • Be able to understand how to apply the new diagnostic guidelines to the diagnosis and treatment of Myeloma.

    Show Resources
    You May Also Like
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    APR 25, 2018 07:00 AM PDT
    C.E. CREDITS
    APR 25, 2018 07:00 AM PDT
    DATE: April 25, 2018TIME: 1500 CET, 10:00 a.m. EST, 7:00 a.m. PST Hematology and coagulation laboratories perform a wide range of routine and specialized tests, allowing clinicians to...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    JUN 29, 2018 09:00 AM PDT
    C.E. CREDITS
    JUN 29, 2018 09:00 AM PDT
    DATE: June 29, 2018TIME: 09:00AM PDT, 12:00PM EDT There is significant epidemiological evidence to suggest that the consumption of a high-broccoli diet is associated with a r...
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    Loading Comments...